TN2015000293A1 - Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases - Google Patents

Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases

Info

Publication number: TN2015000293A1
Authority: TN; Tunisia
Prior art keywords: heterocycle; methods; treatment; tetracyclic compounds; substituted tetracyclic
Prior art date: 2013-01-16

Application number

TNP2015000293A

Other languages

English (en)

Inventor

Wensheng Yu

Ling Tong

Joseph A Kozlowski

Oleg Selyutin

Lei Chen

Jae-Hun Kim

Deyou Sha

Razia Rizvi

Bandarpalle Shankar

Bin Hu

Bin Zhong

Dahai Wang

Jinglai Hao

Wei Wei

Tao Ji

shuai Zan

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-01-16

Filing date

2015-06-29

Publication date

2016-10-03

2015-06-29 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2016-10-03 Publication of TN2015000293A1 publication Critical patent/TN2015000293A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Virology (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

TNP2015000293A 2013-01-16 2015-06-29 Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases TN2015000293A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/CN2013/000038 WO2014110687A1 (fr)	2013-01-16	2013-01-16	Composés tétracycliques substitués par thiazolyle et leurs procédés d'utilisation pour le traitement de maladies virales
PCT/CN2013/001676 WO2014110705A1 (fr)	2013-01-16	2013-12-31	Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales

Publications (1)

Publication Number	Publication Date
TN2015000293A1 true TN2015000293A1 (en)	2016-10-03

Family

ID=51208906

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2015000293A TN2015000293A1 (en)	2013-01-16	2015-06-29	Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases

Country Status (26)

Country	Link
US (1)	US9555038B2 (fr)
EP (1)	EP2945952B1 (fr)
JP (3)	JP6093451B2 (fr)
KR (1)	KR101748974B1 (fr)
CN (1)	CN105073755B (fr)
AP (1)	AP2015008625A0 (fr)
AR (1)	AR094496A1 (fr)
AU (1)	AU2013374112B2 (fr)
BR (1)	BR112015016325A2 (fr)
CA (1)	CA2898049C (fr)
CL (1)	CL2015001971A1 (fr)
CR (1)	CR20150378A (fr)
DO (1)	DOP2015000169A (fr)
EA (1)	EA030554B1 (fr)
EC (1)	ECSP15035530A (fr)
HK (1)	HK1211290A1 (fr)
IL (1)	IL239832A0 (fr)
MA (1)	MA38315B1 (fr)
MD (1)	MD20150075A2 (fr)
MX (1)	MX356203B (fr)
PE (1)	PE20151892A1 (fr)
PH (1)	PH12015501560A1 (fr)
SG (1)	SG11201505536RA (fr)
TN (1)	TN2015000293A1 (fr)
TW (1)	TW201441231A (fr)
WO (2)	WO2014110687A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014110687A1 (fr) *	2013-01-16	2014-07-24	Merck Sharp & Dohme Corp.	Composés tétracycliques substitués par thiazolyle et leurs procédés d'utilisation pour le traitement de maladies virales
US10457690B2 (en)	2015-06-04	2019-10-29	Merck Sharp & Dohme Corp.	Process for preparing substituted tetracyclic heterocycle compounds
US20180228828A1 (en) *	2015-08-04	2018-08-16	Merck Sharp & Dohme Corp.	Fixed-dose combinations of antiviral compounds
WO2017023714A1 (fr) *	2015-08-04	2017-02-09	Merck Sharp & Dohme Corp.	Combinaisons à dose fixée de composés antiviraux
US20190002480A1 (en) *	2015-12-21	2019-01-03	Merck Sharp & Dohme Corp.	Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases
WO2017181383A1 (fr)	2016-04-21	2017-10-26	Merck Sharp & Dohme Corp.	Inhibiteurs du virus de l'hépatite c
JP6958797B2 (ja) *	2016-06-21	2021-11-02	浙江柏拉阿図医薬科技有限公司	Ｃ型肝炎ウイルス阻害剤およびその使用
WO2018032468A1 (fr)	2016-08-18	2018-02-22	Merck Sharp & Dohme Corp.	Composés tétracycliques substitués par hétérocycles et leurs procédés d'utilisation pour le traitement de maladies virales
WO2018032467A1 (fr)	2016-08-18	2018-02-22	Merck Sharp & Dohme Corp.	Composés tétracycliques substitués par chromane et leurs utilisations dans le traitement de maladies virales
CN109206396B (zh) *	2017-07-05	2023-03-28	上海迪赛诺化学制药有限公司	2-c-甲基-4,5-o-(1-甲基乙烯基)-d-阿拉伯糖酸乙酯的制备方法
CN109232612A (zh) *	2017-07-11	2019-01-18	周龙兴	抑制丙肝病毒的化合物、药物组合物及其用途
EP3870183A4 (fr) *	2018-10-26	2022-07-20	Merck Sharp & Dohme Corp.	Formulations de composés antiviraux
EP4355319A4 (fr) *	2021-06-17	2025-01-22	ATEA Pharmaceuticals, Inc.	Polythérapie anti-vhc avantageuse
TW202317145A (zh) *	2021-06-17	2023-05-01	美商亞堤製藥公司	有利之抗hcv組合療法
WO2024259085A2 (fr) *	2023-06-14	2024-12-19	Alexion Pharmaceuticals, Inc.	Procédés de synthèse d'inhibiteurs du facteur d du complément et intermédiaires de ceux-ci

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3927630B2 (ja)	1996-09-27	2007-06-13	エーザイ・アール・アンド・ディー・マネジメント株式会社	ウイルス感染症の予防・治療剤
HUP0302221A3 (en)	2000-09-20	2004-01-28	Merck Patent Gmbh	4-amino-quinazolines
WO2005005442A1 (fr)	2003-07-10	2005-01-20	Paradigm Therapeutics Ltd.	Composes de silicium et leur utilisation
US20070049593A1 (en)	2004-02-24	2007-03-01	Japan Tobacco Inc.	Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
ATE428714T1 (de)	2004-02-24	2009-05-15	Japan Tobacco Inc	Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
WO2007084413A2 (fr)	2004-07-14	2007-07-26	Ptc Therapeutics, Inc.	Procedes de traitement de l’hepatite c
US7153848B2 (en)	2004-08-09	2006-12-26	Bristol-Myers Squibb Company	Inhibitors of HCV replication
WO2006046030A2 (fr)	2004-10-26	2006-05-04	Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa	Derives d'indole tetracyclique utilises en tant qu'agents antiviraux
WO2006093867A1 (fr)	2005-02-28	2006-09-08	The Rockefeller University	Structure de la protéine ns5a du virus de l’hépatite c
US7994360B2 (en)	2005-05-16	2011-08-09	Xtl Biopharmaceuticals Ltd.	Benzofuran compounds
US20110104109A1 (en)	2005-07-13	2011-05-05	Frank Bennett	Tetracyclic indole derivatives and their use for treating or preventing viral infections
PL1910338T3 (pl)	2005-07-14	2011-02-28	Irm Llc	Związki heterotetracykliczne jako mimetyki TPO
US7473784B2 (en)	2005-08-01	2009-01-06	Bristol-Myers Squibb Company	Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
FR2894963A1 (fr)	2005-12-16	2007-06-22	Inst Nat Sante Rech Med	Nouveaux composes interagissant avec pea-15
US7745636B2 (en)	2006-08-11	2010-06-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7642251B2 (en)	2007-08-09	2010-01-05	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
AU2008284304A1 (en)	2007-08-09	2009-02-12	Merck & Co., Inc.	Silicon derivatives as histone deacetylase inhibitors
WO2009023179A2 (fr)	2007-08-10	2009-02-19	Genelabs Technologies, Inc.	Entités chimiques bicycliques azotées pour traiter les infections virales
US7704992B2 (en)	2008-02-13	2010-04-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
KR101492672B1 (ko)	2008-02-13	2015-02-16	브리스톨-마이어스 스큅 컴퍼니	Ｃ형 간염 바이러스 억제제로서의 이미다졸릴 바이페닐 이미다졸
RS53420B (sr)	2008-07-22	2014-12-31	Msd Italia S.R.L.	Kombinacije makrocikličnog jedinjenja hinoksalina koje je inhibitor hcv ns3 proteaze sa drugim hcv sredstvima
WO2010041687A1 (fr)	2008-10-09	2010-04-15	コニカミノルタホールディングス株式会社	Élément de conversion photoélectrique organique, cellule solaire, et réseau de capteurs optiques
WO2010062821A1 (fr)	2008-11-28	2010-06-03	Glaxosmithkline Llc	Composés antiviraux, compositions, et procédés d’utilisation
BRPI0922366B8 (pt)	2008-12-03	2021-05-25	Presidio Pharmaceuticals Inc	composto, composição farmacêutica e uso de um composto
US9150554B2 (en)	2009-03-27	2015-10-06	Presidio Pharmaceuticals, Inc.	Fused ring inhibitors of hepatitis C
US8563513B2 (en)	2009-03-27	2013-10-22	Van Andel Research Institute	Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
MA33209B1 (fr) *	2009-03-27	2012-04-02	Merck Sharp & Dohme	Inhibiteurs de la replication du virus de l'hepatite c
AU2010253790A1 (en)	2009-05-29	2011-12-15	Merck Sharp & Dohme Corp.	Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C
US8221737B2 (en)	2009-06-16	2012-07-17	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US20130156731A1 (en)	2009-12-22	2013-06-20	Kevin X. Chen	Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
WO2011112429A1 (fr)	2010-03-09	2011-09-15	Schering Corporation	Composés tricycliques fusionnés de silyle et leurs méthodes d'utilisation dans le cadre du traitement de maladies virales
BR112013007696A2 (pt) *	2010-09-29	2019-09-24	Merck Sharp & Dohme	composto, composição farmacêutica, usos do referido composto e da referida composição
WO2012040923A1 (fr) *	2010-09-29	2012-04-05	Merck Sharp & Dohme Corp.	Dérivés d'indoles tétracycliques et leurs méthodes d'utilisation pour le traitement de maladies virales
EP2621501A4 (fr) *	2010-09-29	2014-04-09	Merck Sharp & Dohme	Dérives hétérocycliques polycycliques et méthodes pour leur utilisation dans le traitement de maladies virales
WO2014110688A1 (fr) *	2013-01-16	2014-07-24	Merck Sharp & Dohme Corp.	Composés tétracycliques à substitution thiophène et leurs procédés d'utilisation pour le traitement des maladies virales
WO2014110687A1 (fr) *	2013-01-16	2014-07-24	Merck Sharp & Dohme Corp.	Composés tétracycliques substitués par thiazolyle et leurs procédés d'utilisation pour le traitement de maladies virales

2013
- 2013-01-16 WO PCT/CN2013/000038 patent/WO2014110687A1/fr not_active Ceased
- 2013-12-31 WO PCT/CN2013/001676 patent/WO2014110705A1/fr not_active Ceased
- 2013-12-31 EA EA201591328A patent/EA030554B1/ru not_active IP Right Cessation
- 2013-12-31 MA MA38315A patent/MA38315B1/fr unknown
- 2013-12-31 KR KR1020157021818A patent/KR101748974B1/ko not_active Expired - Fee Related
- 2013-12-31 JP JP2015551946A patent/JP6093451B2/ja not_active Expired - Fee Related
- 2013-12-31 MX MX2015009225A patent/MX356203B/es active IP Right Grant
- 2013-12-31 AP AP2015008625A patent/AP2015008625A0/xx unknown
- 2013-12-31 US US14/761,256 patent/US9555038B2/en active Active
- 2013-12-31 CA CA2898049A patent/CA2898049C/fr not_active Expired - Fee Related
- 2013-12-31 CN CN201380074735.2A patent/CN105073755B/zh not_active Expired - Fee Related
- 2013-12-31 EP EP13871363.1A patent/EP2945952B1/fr active Active
- 2013-12-31 PE PE2015001352A patent/PE20151892A1/es not_active Application Discontinuation
- 2013-12-31 SG SG11201505536RA patent/SG11201505536RA/en unknown
- 2013-12-31 HK HK15112117.6A patent/HK1211290A1/xx unknown
- 2013-12-31 MD MDA20150075A patent/MD20150075A2/ro not_active Application Discontinuation
- 2013-12-31 AU AU2013374112A patent/AU2013374112B2/en not_active Ceased
- 2013-12-31 BR BR112015016325A patent/BR112015016325A2/pt not_active Application Discontinuation
2014
- 2014-01-16 AR ARP140100153A patent/AR094496A1/es unknown
- 2014-01-16 TW TW103101674A patent/TW201441231A/zh unknown
2015
- 2015-06-29 TN TNP2015000293A patent/TN2015000293A1/fr unknown
- 2015-07-08 IL IL239832A patent/IL239832A0/en unknown
- 2015-07-13 PH PH12015501560A patent/PH12015501560A1/en unknown
- 2015-07-13 CL CL2015001971A patent/CL2015001971A1/es unknown
- 2015-07-16 CR CR20150378A patent/CR20150378A/es unknown
- 2015-07-16 DO DO2015000169A patent/DOP2015000169A/es unknown
- 2015-08-17 EC ECIEPI201535530A patent/ECSP15035530A/es unknown
2016
- 2016-11-07 JP JP2016217169A patent/JP6148779B2/ja not_active Expired - Fee Related
- 2016-11-18 JP JP2016225137A patent/JP6417380B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20150335648A1 (en)	2015-11-26
EA201591328A1 (ru)	2015-11-30
DOP2015000169A (es)	2015-12-31
ECSP15035530A (es)	2017-08-31
JP2017075158A (ja)	2017-04-20
EP2945952A1 (fr)	2015-11-25
WO2014110705A9 (fr)	2015-03-05
AU2013374112B2 (en)	2016-11-17
PH12015501560A1 (en)	2015-09-21
BR112015016325A2 (pt)	2017-08-22
WO2014110687A1 (fr)	2014-07-24
CN105073755B (zh)	2017-08-18
MA38315A1 (fr)	2017-02-28
KR20150104630A (ko)	2015-09-15
WO2014110705A1 (fr)	2014-07-24
EP2945952B1 (fr)	2019-08-28
JP6148779B2 (ja)	2017-06-14
HK1211290A1 (en)	2016-05-20
JP2017095450A (ja)	2017-06-01
CA2898049C (fr)	2018-04-17
SG11201505536RA (en)	2015-08-28
IL239832A0 (en)	2015-08-31
PE20151892A1 (es)	2015-12-24
JP2016510321A (ja)	2016-04-07
MA38315B1 (fr)	2018-05-31
CL2015001971A1 (es)	2015-10-23
US9555038B2 (en)	2017-01-31
MX356203B (es)	2018-05-18
AR094496A1 (es)	2015-08-05
JP6417380B2 (ja)	2018-11-07
KR101748974B1 (ko)	2017-06-19
MX2015009225A (es)	2015-10-15
AU2013374112A1 (en)	2015-07-16
CR20150378A (es)	2015-12-09
EA030554B1 (ru)	2018-08-31
AP2015008625A0 (en)	2015-07-31
CN105073755A (zh)	2015-11-18
TW201441231A (zh)	2014-11-01
CA2898049A1 (fr)	2014-07-24
EP2945952A4 (fr)	2016-07-20
MD20150075A2 (ro)	2016-02-29
JP6093451B2 (ja)	2017-03-08

Publication	Publication Date	Title
TN2015000293A1 (en)	2016-10-03	Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
TN2012000416A1 (en)	2014-01-30	Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
MX2013003634A (es)	2013-05-20	Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
WO2012018534A3 (fr)	2013-07-18	Composés de biphénylène substitué et procédés d'utilisation desdits composés pour le traitement de maladies virales
WO2012142093A3 (fr)	2013-02-07	Dérivés nucléosides à substitution 2'-cyano et leurs procédés d'utilisation pour traitement de maladies virales
TN2013000421A1 (en)	2015-03-30	2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
MX2022013596A (es)	2022-11-16	Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
WO2012125926A3 (fr)	2014-05-08	Dérivés tétracycliques de xanthène et leurs méthodes d'utilisation en vue du traitement de maladies virales
PH12015502443A1 (en)	2016-02-22	6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
NZ703064A (en)	2016-12-23	Inhibitors of hepatitis c virus
PH12014500164A1 (en)	2016-10-19	Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
NZ631726A (en)	2017-01-27	Therapeutic compounds for the treatment of viral infections
EA026667B9 (ru)	2017-07-31	Фармацевтическая композиция для лечения вируса гепатита с
EA201490647A1 (ru)	2014-12-30	Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
MX2017007814A (es)	2017-09-18	Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
MX355267B (es)	2018-04-12	Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
NZ631754A (en)	2017-02-24	Amide compounds for the treatment of hiv
MX2017012393A (es)	2018-02-21	Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
IN2012DN01855A (fr)	2015-08-21
IN2014MN01547A (fr)	2015-05-08
MX350746B (es)	2017-09-14	Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral.
PH12015500111A1 (en)	2015-03-30	Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
MX342153B (es)	2016-09-15	Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.